Logo

NeoGenomics Immuno-Oncology Profiling Tests

Jun 02, 2017

NeoGenomics has launched an expansion of its NeoTYPE cancer profiles to include Tumor Mutation Burden (TMB) and microsatellite instability (MSI) testing. TMB is a new genomic biomarker that is designed to predict response to checkpoint inhibitor immunotherapies targeting the PD-1 and PD-L1 proteins. The TMB tests will be available on a standalone basis, and in combination with the various cancer-specific NewTYPE tests, the company said. MSI testing will be offered to patients to identify metastatic solid tumors that are MSI-high or mismatch repair deficient (MMR). They company is offering MSI testing as a result of the FDA's recent approval of Merck's Keytruda drug to treat patients identified to have MSI-high or MMR tumors.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.